Thymosin Alpha-1: The Immune-Boosting Peptide Your Doctor Should Know About

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Ta1), also known by its pharmaceutical name thymalfasin and marketed internationally under the brand name Zadaxin, is a naturally occurring peptide composed of 28 amino acids that plays a central role in the maturation and regulation of the immune system. It was first isolated from thymic tissue — the thymus gland, a small organ behind the sternum that serves as the primary training ground for T-lymphocytes, the immune cells responsible for adaptive immunity.

Discovered by Dr. Allan Goldstein at the George Washington University in the 1970s, Thymosin Alpha-1 was one of the first peptides to demonstrate that the thymus gland produces soluble factors capable of modulating immune function throughout the body. This discovery fundamentally changed our understanding of immune regulation and opened the door to a new class of immunomodulatory therapeutics.

What makes Thymosin Alpha-1 particularly remarkable is its dual nature: it can both enhance an underactive immune system and modulate an overactive one. This bidirectional activity distinguishes it from simple immune stimulants and positions it as a true immune regulator — a property that has made it invaluable across a wide range of clinical applications, from chronic viral infections to autoimmune diseases to cancer immunotherapy.

The Science Behind Thymosin Alpha-1

The Thymus Gland and Immune Aging

To appreciate why Thymosin Alpha-1 matters, it's essential to understand the thymus gland's role in immune function — and what happens when it deteriorates.

The thymus gland is most active during childhood and adolescence, when it produces the naive T-cells that form the backbone of adaptive immunity. Beginning around puberty, the thymus undergoes a process called thymic involution — a gradual shrinkage and replacement of functional thymic tissue with fat. By age 50, the thymus has lost approximately 80-90% of its functional capacity. By age 70, thymic output is negligible in most individuals.

This decline has profound consequences for immune competence:

• Reduced production of naive T-cells, limiting the ability to mount responses against novel pathogens
• Shrinking T-cell receptor repertoire, narrowing the range of infections and cancers the immune system can recognize
• Increased susceptibility to infections, particularly viral infections like influenza, RSV, and COVID-19
• Impaired vaccine responses, explaining why elderly individuals often derive less protection from vaccination
• Increased cancer risk, as immune surveillance for malignant cells diminishes
• Paradoxical increase in autoimmunity and chronic inflammation ("inflammaging"), as regulatory T-cell function declines

Thymosin Alpha-1 essentially provides the signaling molecules that the aging thymus can no longer produce in sufficient quantities. By supplementing these thymic peptides exogenously, it becomes possible to partially restore immune functions that have been lost to aging.

Mechanism of Action

Thymosin Alpha-1 exerts its immunomodulatory effects through multiple interconnected pathways:

1. T-Cell Maturation and Differentiation

Ta1 promotes the differentiation of immature thymocytes into functional T-cell subsets, including CD4+ helper T-cells and CD8+ cytotoxic T-cells. It upregulates the expression of T-cell surface markers (CD2, CD3, CD4, CD8) on progenitor cells, effectively accelerating the maturation process that normally occurs within the thymus.

2. Dendritic Cell Activation

Ta1 activates dendritic cells (DCs), the professional antigen-presenting cells that serve as the bridge between innate and adaptive immunity. By enhancing DC function, Ta1 improves the immune system's ability to recognize, process, and present foreign antigens to T-cells, initiating more robust adaptive immune responses.

3. Toll-Like Receptor Signaling

Ta1 acts as an agonist at Toll-like receptors TLR2 and TLR9, pattern recognition receptors on innate immune cells that detect pathogen-associated molecular patterns. This activation triggers downstream signaling cascades including NF-kB and IRF7, leading to enhanced production of antiviral cytokines including interferons alpha and gamma.

4. Natural Killer Cell Enhancement

Ta1 increases the activity and cytotoxicity of natural killer (NK) cells, which are responsible for the rapid destruction of virus-infected and tumor cells without requiring prior sensitization. Enhanced NK function is particularly important for antiviral and anticancer immunity.

5. Regulatory T-Cell Modulation

Perhaps most importantly for autoimmune applications, Ta1 promotes the development and function of regulatory T-cells (Tregs), which suppress excessive immune activation and maintain immune tolerance. This explains the paradoxical ability of Ta1 to enhance immune responses against pathogens while simultaneously calming autoimmune inflammation.

"Thymosin Alpha-1 is unique among immune therapies because it doesn't simply turn the immune system up or down — it recalibrates it. It restores the balance between immune activation and immune regulation that is lost with aging and disease." — Dr. Enrico Garaci, former President of the Italian National Institute of Health

Clinical Evidence: Approved in Over 35 Countries

One of the most compelling aspects of Thymosin Alpha-1 is the breadth and depth of its clinical evidence. While it has never received FDA approval in the United States, it is an approved pharmaceutical product in over 35 countries, including Italy, China, India, Argentina, the Philippines, and many nations across Asia, South America, and Europe. Its international brand name, Zadaxin, has been prescribed to millions of patients worldwide since the 1990s.

Hepatitis B

The strongest clinical evidence for Thymosin Alpha-1 exists in the treatment of chronic hepatitis B virus (HBV) infection. Multiple randomized controlled trials have demonstrated that Ta1, either as monotherapy or in combination with interferon-alpha, significantly increases:

• HBV DNA clearance rates
• HBeAg seroconversion rates
• Sustained virological response — with response rates continuing to improve for 6-12 months after completing treatment, a unique characteristic suggesting durable immune reconstitution

A landmark meta-analysis published in the Journal of Viral Hepatitis pooled data from multiple randomized trials and found that Ta1 therapy significantly improved the odds of complete virological response compared to interferon monotherapy, with a notably superior side effect profile.

Hepatitis C

Prior to the development of direct-acting antiviral agents (DAAs), Thymosin Alpha-1 was studied extensively as a component of combination therapy for chronic hepatitis C. Clinical trials demonstrated improved sustained virological response rates when Ta1 was added to pegylated interferon and ribavirin regimens, particularly in patients with genotypes that were traditionally difficult to treat.

While the advent of DAAs (sofosbuvir, ledipasvir, etc.) has largely supplanted interferon-based HCV treatment in developed nations, Ta1 remains relevant in resource-limited settings where DAA access is inconsistent, and for patients who fail or cannot tolerate DAA therapy.

Cancer Immunotherapy

Thymosin Alpha-1 has been studied as an adjunctive therapy in multiple cancer types, including hepatocellular carcinoma, melanoma, non-small cell lung cancer, and renal cell carcinoma. Its role in oncology is primarily as an immune adjuvant — enhancing the anti-tumor immune response rather than directly killing cancer cells.

Clinical trials have demonstrated that adding Ta1 to chemotherapy, radiation, or other immunotherapies can:

• Improve overall survival in hepatocellular carcinoma patients
• Reduce immunosuppressive side effects of chemotherapy
• Enhance response rates to checkpoint inhibitor immunotherapy
• Improve quality of life and reduce infection rates during cancer treatment

Sepsis and Critical Illness

One of the most exciting recent applications of Thymosin Alpha-1 has been in the treatment of sepsis, a life-threatening condition in which the body's response to infection causes widespread organ damage. Sepsis kills approximately 270,000 Americans annually and remains one of the most challenging conditions in critical care medicine.

A landmark randomized controlled trial published in Critical Care Medicine evaluated Ta1 in patients with severe sepsis and found:

• 28-day mortality reduction from 35% to 26% (a relative reduction of approximately 25%)
• Restoration of HLA-DR expression on monocytes — a key marker of immune competence that is suppressed in sepsis
• Rebalancing of pro-inflammatory and anti-inflammatory cytokine profiles
• Improved CD4/CD8 T-cell ratios

These findings have led to the inclusion of Thymosin Alpha-1 in the Chinese Sepsis Treatment Guidelines and ongoing multicenter trials in other countries. The ability of Ta1 to reverse the immune paralysis that characterizes severe sepsis — without exacerbating the inflammatory storm — represents a unique therapeutic advantage.

Chronic Infections and Autoimmune Conditions

Chronic and Recurrent Infections

Beyond hepatitis, Thymosin Alpha-1 has been investigated and used clinically for a wide range of chronic and recurrent infections, including:

• HIV/AIDS — as an immune adjuvant to antiretroviral therapy, improving CD4 counts and reducing opportunistic infections
• Cytomegalovirus (CMV) — particularly in immunocompromised transplant recipients
• Chronic Lyme disease — used by integrative practitioners to restore immune competence in patients with persistent symptoms
• Recurrent respiratory infections — reducing frequency and severity of infections in elderly and immunocompromised patients
• Chronic fungal infections — enhancing cell-mediated immunity against persistent fungal pathogens

In each of these applications, Ta1's value lies in its ability to restore the qualitative function of the immune system — not just increasing cell counts, but improving the functional capacity of existing immune cells to recognize and eliminate pathogens.

Autoimmune Conditions

The immunomodulatory (rather than purely immunostimulatory) nature of Thymosin Alpha-1 makes it relevant for autoimmune conditions, where the immune system attacks the body's own tissues. By promoting regulatory T-cell function and restoring immune balance, Ta1 can help calm autoimmune inflammation without the broad immunosuppression associated with conventional autoimmune therapies.

Clinical and observational evidence suggests potential benefit in:

• Rheumatoid arthritis — reducing inflammatory markers and improving clinical response to disease-modifying antirheumatic drugs (DMARDs)
• Multiple sclerosis — preliminary evidence of improved regulatory T-cell function
• Chronic fatigue syndrome/ME — addressing the immune dysregulation component of these complex conditions
• Hashimoto's thyroiditis — modulating the autoimmune attack on thyroid tissue
• Psoriasis — reducing Th17-mediated skin inflammation while enhancing Treg activity

It is important to note that autoimmune applications of Ta1 remain largely off-label and are based on clinical experience and smaller studies rather than large Phase 3 trials. Patients considering Ta1 for autoimmune conditions should work with a provider experienced in both peptide therapy and autoimmune disease management.

Age-Related Immune Decline: Immunosenescence

Perhaps the most broadly relevant application of Thymosin Alpha-1 is in addressing immunosenescence — the progressive decline in immune function that accompanies aging. As described earlier, thymic involution leads to a cascade of immune deficits that increase susceptibility to infections, cancer, and chronic disease.

The Case for Immune Restoration

The concept of using Thymosin Alpha-1 for age-related immune decline is grounded in a simple but powerful logic: if immune aging is driven in large part by declining thymic output, then replacing thymic peptides should at least partially reverse these changes. Clinical and preclinical evidence supports this rationale:

• Increased naive T-cell production in elderly subjects treated with Ta1
• Improved vaccine responsiveness — studies have shown that Ta1 enhances antibody responses to influenza vaccination in the elderly by 25-40%
• Enhanced NK cell cytotoxicity in aging subjects
• Reduced markers of chronic inflammation (IL-6, TNF-alpha, CRP) — the "inflammaging" that drives many age-related diseases

These findings have positioned Thymosin Alpha-1 as a cornerstone of many longevity medicine and anti-aging protocols. Providers specializing in age management increasingly include Ta1 alongside other interventions such as growth hormone peptides, NAD+ precursors, and senolytics.

Practical Protocols for Immune Support

Common Thymosin Alpha-1 dosing protocols for general immune support and anti-aging include:

• Standard protocol: 1.6 mg subcutaneously, 2-3 times per week
• Intensive protocol (acute illness): 1.6 mg daily for 7-14 days, then tapering to maintenance
• Maintenance/prevention: 1.6 mg once or twice weekly on an ongoing basis
• Pre-travel or pre-exposure prophylaxis: 1.6 mg daily starting 5-7 days before anticipated exposure

Thymosin Alpha-1 is administered via subcutaneous injection, typically in the abdomen or thigh. It is well-tolerated with an excellent safety profile — no serious adverse events have been attributed to Ta1 in clinical trials or post-marketing surveillance across millions of doses administered worldwide.

Post-COVID Applications

The COVID-19 pandemic brought Thymosin Alpha-1 into mainstream medical attention, particularly in countries where it was already available as an approved medication. Multiple clinical protocols incorporated Ta1 for both acute COVID-19 treatment and long COVID management.

Acute COVID-19

During the pandemic, several studies evaluated Thymosin Alpha-1 in hospitalized COVID-19 patients. Key findings included:

• Reduced mortality in critically ill patients when Ta1 was added to standard of care
• Faster recovery of lymphocyte counts — COVID-19 characteristically causes lymphopenia (low lymphocyte counts), and Ta1 accelerated immune reconstitution
• Reduced progression to mechanical ventilation in some patient subgroups
• Restoration of T-cell function as measured by cytokine production capacity

A retrospective study published in Clinical Infectious Diseases analyzing over 300 critically ill COVID-19 patients found that those who received Thymosin Alpha-1 had significantly lower 28-day mortality, particularly among patients with severe lymphopenia (CD4+ T-cell counts below 400/uL). This subgroup analysis was particularly compelling because it identified the patients most likely to benefit — those with the most profound immune suppression.

Long COVID and Post-Acute Sequelae

As the pandemic evolved, attention shifted to the millions of individuals suffering from long COVID (Post-Acute Sequelae of SARS-CoV-2, or PASC). Emerging evidence suggests that many long COVID symptoms are driven by persistent immune dysregulation, including:

• Chronic T-cell exhaustion — T-cells that remain activated but functionally impaired
• Persistent viral reservoirs — fragments of SARS-CoV-2 RNA and protein persisting in tissues
• Autoimmune phenomena — molecular mimicry leading to autoantibody production
• Dysregulated interferon signaling

Thymosin Alpha-1's ability to address multiple components of this immune dysregulation has made it a popular intervention among long COVID specialists. Anecdotal and early clinical evidence from long COVID treatment programs suggests that Ta1 can improve fatigue, cognitive function ("brain fog"), exercise tolerance, and susceptibility to recurrent infections in long COVID patients.

"In our long COVID clinic, Thymosin Alpha-1 has become one of our most reliable interventions. We see improvements in T-cell function panels within 4-6 weeks, often accompanied by meaningful clinical improvement. It addresses the immune dysregulation that underlies many of these patients' symptoms." — Dr. Bruce Patterson, IncellDx CEO and long COVID researcher

Vaccine Enhancement

Ta1 has also been investigated as a vaccine adjuvant — administered alongside or shortly before vaccination to enhance the immune response. This application is particularly relevant for elderly individuals and immunocompromised patients who may not generate adequate antibody responses to vaccines alone. Studies have shown improved antibody titers and more durable immune responses when Ta1 is co-administered with influenza, hepatitis B, and COVID-19 vaccines.

The 2026 FDA Reclassification Landscape

The regulatory status of Thymosin Alpha-1 in the United States has been a source of ongoing discussion and some controversy. Despite being approved in over 35 countries with an extensive safety and efficacy record, Ta1 has never received FDA approval. It has historically been available in the US through compounding pharmacies as a Category 1 compounded peptide under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

The FDA's Peptide Reclassification Initiative

Beginning in late 2023, the FDA undertook a comprehensive review of compounded peptides, evaluating which peptides should remain eligible for compounding and which should require new drug applications (NDAs) for continued availability. This initiative, which intensified through 2024 and 2025, has had significant implications for the peptide therapy community.

As of early 2026, Thymosin Alpha-1's status remains somewhat uncertain. It is on the FDA's list of peptides under evaluation, and several outcomes are possible:

• Continued compounding eligibility: Ta1 remains available through licensed compounding pharmacies as it has been historically
• Bulk drug substance designation: Ta1 is formally recognized as an approved bulk drug substance for compounding, providing greater regulatory clarity
• Restricted availability: The FDA could require that Ta1 only be available through 503B outsourcing facilities (not individual 503A pharmacies), limiting access
• Removal from compounding: In the most restrictive scenario, the FDA could determine that Ta1 must go through the NDA process, effectively removing it from the US market until a manufacturer completes formal FDA approval

The peptide therapy community, along with several physician advocacy organizations and patient groups, has been actively lobbying for continued compounding access to Thymosin Alpha-1, citing its extensive international safety record and the unmet medical need for immunomodulatory therapies.

What This Means for Patients

If you are currently using or considering Thymosin Alpha-1, the regulatory landscape means:

• Work with a knowledgeable provider who stays current on regulatory developments
• Use licensed compounding pharmacies — preferably 503B outsourcing facilities, which are subject to more rigorous FDA oversight
• Document your treatment history and clinical response — this information may be valuable if access changes occur
• Stay informed — monitor PeptideProbe and other reliable sources for updates on FDA reclassification decisions

Finding a Provider for Thymosin Alpha-1 Therapy

Given the complexity of immune modulation and the evolving regulatory landscape, finding the right provider for Thymosin Alpha-1 therapy is particularly important.

Ideal Provider Qualifications

• Board certification in immunology, infectious disease, rheumatology, or integrative/functional medicine
• Demonstrated expertise in peptide therapy — ask about their experience specifically with Thymosin Alpha-1 and the clinical conditions they treat with it
• Comprehensive immune evaluation capability — a good provider will order baseline immune panels including lymphocyte subsets (CD4, CD8, NK cells), immunoglobulin levels, cytokine panels, and other relevant markers before and during treatment
• Relationships with licensed compounding pharmacies — ideally 503B outsourcing facilities that maintain cGMP standards and provide certificates of analysis for each batch
• Willingness to monitor and adjust — immune modulation requires ongoing assessment and dosing adjustment based on laboratory and clinical response

What to Expect at Your First Visit

A thorough initial evaluation for Thymosin Alpha-1 therapy should include:

• Detailed medical history focusing on infection history, autoimmune conditions, cancer history, vaccination responses, and current medications
• Physical examination with attention to lymph nodes, thyroid, and signs of chronic infection or inflammation
• Baseline laboratory testing including complete blood count with differential, comprehensive metabolic panel, inflammatory markers (CRP, ESR, ferritin), vitamin D level, and immune function panels
• Discussion of treatment goals — whether you're seeking improved infection resistance, autoimmune management, post-COVID recovery, or general immune optimization
• Review of potential interactions with current medications and other therapies

Using PeptideProbe to Find a Provider

PeptideProbe's provider directory includes clinics and practitioners experienced in Thymosin Alpha-1 therapy across the United States. You can search by location, specialty, and specific conditions treated. Each listing includes verified credentials, patient reviews, and information about the provider's approach to immune health.

Thymosin Alpha-1 in Integrative and Functional Medicine

Beyond its established clinical applications, Thymosin Alpha-1 has become a cornerstone of many integrative and functional medicine practices, where it is used as part of comprehensive health optimization protocols. This broader adoption reflects a growing recognition that immune function is not merely about fighting infections — it is central to overall health, aging, and disease prevention.

Chronic Inflammatory Response Syndrome (CIRS)

Practitioners specializing in environmentally acquired illnesses, particularly mold-related illness and chronic inflammatory response syndrome (CIRS), have incorporated Thymosin Alpha-1 into treatment protocols. CIRS patients often exhibit profound immune dysregulation, including abnormal cytokine profiles, reduced natural killer cell function, and impaired T-regulatory cell activity. Ta1's ability to restore immune balance — enhancing protective immunity while dampening inappropriate inflammatory responses — aligns well with the therapeutic goals in CIRS management.

Clinical experience from CIRS specialists suggests that Thymosin Alpha-1, when combined with environmental remediation and other components of the Shoemaker protocol, can accelerate immune recovery and reduce the chronic inflammation that drives CIRS symptoms including fatigue, cognitive dysfunction, joint pain, and respiratory complaints.

Tick-Borne Illness and Co-Infections

Patients with chronic tick-borne infections — including Lyme disease (Borrelia burgdorferi), Bartonella, Babesia, and Ehrlichia — often present with complex immune dysfunction that persists even after appropriate antimicrobial therapy. Thymosin Alpha-1 is increasingly used in Lyme-literate medical practices to support immune reconstitution alongside antimicrobial treatment. The peptide's ability to enhance both innate (NK cell) and adaptive (T-cell) immunity may help the body clear persistent intracellular organisms that evade antibiotic therapy alone.

Preventive Health and Immune Resilience

A growing number of health-conscious individuals without specific disease diagnoses are using Thymosin Alpha-1 as a proactive immune optimization strategy. This preventive approach is particularly popular among:

• Frequent travelers exposed to novel pathogens and immune-stressing environments
• Healthcare workers with high pathogen exposure risk
• Individuals over 50 seeking to counteract age-related immune decline
• Athletes and high-performers whose intense training regimens can temporarily suppress immune function
• Cancer survivors seeking to support immune surveillance against recurrence

While the evidence base for purely preventive use is less robust than for specific disease indications, the rationale is grounded in well-established immunology: a more competent immune system is better equipped to recognize and eliminate threats before they become clinical illnesses. The excellent safety profile of Thymosin Alpha-1 makes this prophylactic application reasonable from a risk-benefit perspective, though patients should work with knowledgeable providers to design appropriate protocols.

Side Effects and Safety Profile

Thymosin Alpha-1 has one of the best safety profiles of any therapeutic peptide. In clinical trials involving thousands of patients and decades of post-marketing surveillance across 35+ countries, the following has been consistently observed:

• No serious adverse events directly attributed to Ta1
• No immunosuppressive effects — unlike many immune-modulating drugs, Ta1 does not increase susceptibility to infections
• No organ toxicity — liver, kidney, cardiac, and hematological safety parameters remain normal during treatment
• No drug interactions of clinical significance have been identified

Minor side effects that have been reported include:

• Injection site reactions — mild redness, swelling, or tenderness that typically resolves within 24 hours
• Mild flu-like symptoms — occasionally reported during the first few days of treatment, likely reflecting immune activation
• Fatigue — transient tiredness that may occur as the immune system recalibrates

This favorable safety profile makes Thymosin Alpha-1 suitable for long-term use and for vulnerable populations including the elderly and immunocompromised — the very populations most likely to benefit from immune restoration therapy.

Frequently Asked Questions About Thymosin Alpha-1

How long does it take for Thymosin Alpha-1 to work?

Most patients begin to notice clinical improvements within 2-6 weeks of initiating therapy. Laboratory markers of immune function (lymphocyte subsets, NK cell activity) typically show measurable changes within 4-8 weeks. However, the full benefits of immune reconstitution may continue to develop over 3-6 months of consistent treatment.

Can I take Thymosin Alpha-1 if I have an autoimmune condition?

Yes, in many cases. Unlike pure immune stimulants, Ta1 promotes immune balance by enhancing regulatory T-cell function. Many clinicians use it successfully in autoimmune patients. However, it should be initiated under the guidance of a provider experienced in both peptide therapy and autoimmune disease, with careful monitoring of disease activity markers.

Is Thymosin Alpha-1 the same as thymus extract?

No. Thymosin Alpha-1 is a specific, synthetic, 28-amino-acid peptide with a defined molecular structure. Thymus extracts (sometimes sold as "thymus glandulars") are crude preparations of animal thymus tissue containing hundreds of different proteins and peptides in undefined proportions. The two are not interchangeable, and thymus extracts do not replicate the specific biological activity of purified Ta1.

Can Thymosin Alpha-1 be combined with other peptides?

Yes, Ta1 is frequently combined with other therapeutic peptides. Common combinations include Ta1 with BPC-157 (for combined immune and tissue repair support), Ta1 with growth hormone peptides (for comprehensive anti-aging protocols), and Ta1 with thymosin beta-4 (for enhanced tissue repair alongside immune modulation). Your provider can design a combination protocol based on your specific clinical needs.

How is Thymosin Alpha-1 stored?

Lyophilized (freeze-dried) Ta1 should be stored refrigerated at 2-8 degrees Celsius. Once reconstituted with bacteriostatic water, it should be kept refrigerated and used within 28-30 days. Never freeze reconstituted peptide solutions, and discard any vial that shows cloudiness, particulate matter, or discoloration.

Conclusion: A Peptide Whose Time Has Come

Thymosin Alpha-1 occupies a unique position in the peptide therapy landscape. Backed by decades of clinical research, approved in over 35 countries, and with an unparalleled safety record, it offers a scientifically grounded approach to immune modulation that addresses some of the most pressing health challenges of our time — from chronic infections and autoimmune disease to age-related immune decline and post-COVID recovery.

The paradox of Thymosin Alpha-1's regulatory situation in the United States — extensively proven yet never FDA-approved — reflects broader challenges in the way peptide therapeutics are evaluated and made available. As the FDA's reclassification process continues through 2026, patients and providers who understand Ta1's evidence base are in the best position to advocate for continued access to this valuable therapy.

If immune health is a concern for you — whether due to recurrent infections, autoimmune conditions, aging, or post-COVID symptoms — Thymosin Alpha-1 deserves a conversation with a knowledgeable healthcare provider. Use PeptideProbe's directory to find a qualified clinic in your area that offers evidence-based immune peptide therapy.

Medical Disclaimer: This article is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Thymosin Alpha-1 is not FDA-approved in the United States and is available through compounding pharmacies by prescription only. PeptideProbe does not sell, prescribe, or endorse any specific medication or treatment.